Matthew Luchini
Stock Analyst at BMO Capital
(2.04)
# 2,989
Out of 5,111 analysts
34
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $9.61 | +212.17% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $1.71 | +11,011.11% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $25.31 | +172.62% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $24.13 | +331.00% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $2.26 | +2,333.63% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $11.90 | +748.74% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $746.36 | -15.59% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $554.57 | -77.64% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $118.78 | -46.12% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $35.72 | -60.81% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.14 | +5,163.16% | 2 | Dec 3, 2019 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $9.61
Upside: +212.17%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $1.71
Upside: +11,011.11%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $25.31
Upside: +172.62%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $24.13
Upside: +331.00%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $2.26
Upside: +2,333.63%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $11.90
Upside: +748.74%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $746.36
Upside: -15.59%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $554.57
Upside: -77.64%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $118.78
Upside: -46.12%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $35.72
Upside: -60.81%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.14
Upside: +5,163.16%